glp-1 analog drugs Mapping the effectiveness and risks of receptor agonists Frontiers | GLP-1 Receptor Agonists:

11 On average, patients regain one-third of the weight lost (510% of baseline bodyweight) within the first year of treatment discontinuation, and nearly half of patients return to their initial weight within five years

Tirzepatides dual GLP-1R and GIPR agonism may confer distinct anti-inflammatory effects, some of which persist even when neuronal GLP-1R signaling is impaired

In the LIVE study, which examined the effects of liraglutide in patients with stable HFrEF, no changes in LVEF were observed

Although investigations in animals are scarce, studies among humans have suggested that GLP-1 RAs directly mitigate the development of coronary atherosclerosis through several mechanisms (Table 1)

If needle fear is the barrier, the Wegovy oral pill eliminates injections entirely while delivering 14% weight loss with Phase 3 evidence

Our DEXA Body Composition, Bone Density, and Visceral Fat page explains why measuring body composition can be more clinically useful than relying on weight alone